艾迪藥業(688488.SH):與中國醫保簽訂戰略合作協議
格隆匯12月9日丨艾迪藥業(688488.SH)公佈,公司與中國醫藥保健品有限公司(“中國醫保”)經友好協商,達成戰略合作意向並於近日簽訂了《戰略合作協議》。
艾迪藥業與中國醫保雙方基於對中國醫藥行業的現狀與發展趨勢的共識,在“誠信協作、優勢互補,責任共擔、資源共享”原則上擴大合作領域的廣度和深度,以進一步共享優勢資源,降低成本、提高效率,提高企業抗風險能力,實現共贏,為雙方的客户創造更大價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.